enGene Therapeutics Inc. (ENGN)

NASDAQ: ENGN · Real-Time Price · USD

2.000

+0.050 (2.56%)

At close: Sep 30, 2026, 4:00 PM EDT

1.890

-0.110 (-5.50%)

Pre-market: Oct 1, 2026, 4:11 AM EDT

enGene Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 31, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Net Income	-130.36	-117.3	-55.14	-99.92	-24.46	-23.44
Depreciation & Amortization	0.72	0.51	0.32	0.18	0.24	0.27
Other Amortization	-	-	-	0.92	-	-
Loss (Gain) From Sale of Assets	-	-	0.02	-	-	-
Loss (Gain) From Sale of Investments	-1.79	-3.07	-0.23	-	-	-
Stock-Based Compensation	17.36	9.65	5.32	3.45	0.12	0.44
Other Operating Activities	2.19	1.24	1.33	71.14	4.34	7.79
Change in Accounts Payable	-0.18	4.94	0.47	0.37	-0.2	0.11
Change in Other Net Operating Assets	8.87	5.39	-2.39	0.12	2.23	-1.44
Operating Cash Flow	-103.31	-99.24	-48.28	-24.74	-17.59	-15.98
Operating Cash Flow Growth	-	-	-	-	-	-

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 31, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Capital Expenditures	-0.69	-1.49	-0.93	-0.32	-0.15	-0.25
Sale of Property, Plant & Equipment	-	-	-	-	-	0
Investment in Securities	-31.35	-23.65	-125.03	-	-	-
Investing Cash Flow	-32.04	-25.14	-125.95	-0.32	-0.15	-0.25

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 31, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Long-Term Debt Issued	-	-	22.5	38	29.4	8.03
Long-Term Debt Repaid	-	-0.7	-9.45	-4.73	-1.01	-0.96
Net Debt Issued (Repaid)	1.95	-0.7	13.06	33.27	28.39	7.07
Issuance of Common Stock	151.79	2.22	266.25	56.94	0.01	0.01
Other Financing Activities	-9.99	-	-13.58	-4.06	-0.44	-0.14
Financing Cash Flow	143.75	1.52	265.72	86.15	27.97	22.53

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 31, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Foreign Exchange Rate Adjustments	0	0	0	0	-0.81	0.1
Net Cash Flow	8.4	-122.85	91.48	61.09	9.42	6.39

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 31, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Free Cash Flow	-104	-100.72	-49.21	-25.06	-17.75	-16.23
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-1.61	-1.97	-1.30	-36.18	-27.09	-4.56
Levered Free Cash Flow	-60.85	-60.38	-32.23	-16.07	-10.75	-
Unlevered Free Cash Flow	-58.93	-58.51	-30.48	-13.89	-9.86	-

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 31, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Cash Interest Paid	2.3	2.29	1.93	-	0.62	-
Change in Working Capital	8.42	9.74	0.1	-0.52	2.17	-1.04

SEC Filings: 10-K · 10-Q